News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials), the pharmaceutical firm, said its second-quarter earnings topped Wall Street estimates and boosted its annual revenue guidance, as growth in its non-COVID portfolio compensated for a steep drop in Paxlovid sales.Adjusted earnings of 77 …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%Pfizer beat second-quarter expectations Tuesday, offsetting a continued steep decline for its Covid products. But Pfizer stock fell. Continue Reading
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%Pfizer (PFE) reported $15.03 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 2.6%. EPS of $0.77 for the same period compares to $0.78 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $14.45 billion, …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%Pfizer's (NYSE:PFE) Q2 CY2026: Beats On Revenue Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 2.6% year on year to $15.03 billion. The company expects the full year's revenue to be around $61.5 billion, …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo. The company plans to pursue global regulatory filings for LITFULO as …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%Pfizer reported a second-quarter loss of $248 million, or 4 cents a share, despite a 3% increase in revenue to $15.03 billion. The company's revenue growth was driven by its oncology business, which helped to offset declining sales of its Covid-19 products. This contrasts …
Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. Continue Reading
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months Announces Expansion of Productivity Enhancement Initiatives NEW YORK, August 04, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%As U.S. stock futures trade higher, several companies are poised for investor attention on Tuesday. Caterpillar (NYSE: CAT) and McDonald's (NYSE: MCD) are expected to report quarterly earnings, while Palantir Technologies (NASDAQ: PLTR), Snap Inc (NYSE: SNAP), and Pfizer Inc (NYSE: PFE) have already …
Pfizer beat Wall Street expectations for its second-quarter 2026 earnings and raised its full-year revenue guidance midpoint. The company reported adjusted earnings of $0.77 per share and revenue of $15.03 billion, driven by growth in new and acquired products, which offset declines in its …
This article provides a revenue breakdown for Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S (NEO:PFE). It highlights that the United States was the primary contributor to the company's revenue, generating 51.81 billion CAD last year and 53.01 billion CAD …
This article provides a round-up of Pfizer's social media activities in July, highlighting various discussions, achievements, and scientific insights. It covers topics like living with alopecia areata, a Pfizer colleague's cancer survival story, and reflections on scientific advancements. The summary also notes leadership updates, …
Pfizer (PFE) Q2 Earnings: What To Expect Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here's what to expect. Pfizer beat analysts' revenue expectations last quarter, reporting revenues of $14.45 billion, up 5.4% year on year. It was …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%This article lists ETFs that hold Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs stocks, highlighting one specific fund: the CTBC Global High Dividend ETF Securities Investment Trust Fund. It provides financial details such as market value, weight, issuer, management style, expense ratio, …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Pfizer stock has declined 27.7% over the past 5 years, yet the current valuation checks and market multiples now point to a picture that looks …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%Pfizer offers an attractive 6.8% dividend yield and trades at 8.5x forward earnings, with a promising late-stage weight loss drug in its pipeline. Despite these positives, its stock has been stagnant due to recent negative revenue growth and upcoming patent expirations for key products …
Sharemaestro market context Price above Trend Line 52 weeks -4.3%Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. …
Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have returned …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%Pfizer has announced positive topline data from two Phase 3 clinical trials for LITFULO, its once-daily treatment for nonsegmental vitiligo (NSV). The trials showed significant improvements in skin repigmentation, leading Pfizer to prepare global regulatory submissions for the drug. LITFULO, previously approved for severe …
Pfizer announced that its oral drug Litfulo successfully restored skin pigmentation in patients with nonsegmental vitiligo during two late-stage trials. The drug significantly improved facial and total-body repigmentation, paving the way for global regulatory submissions. Litfulo, which blocks specific immune cell proteins, is already …
Pfizer announced positive topline results from two Phase 3 trials (TRANQUILLO and TRANQUILLO 2) evaluating LITFULO (ritlecitinib) for nonsegmental vitiligo (NSV). The studies demonstrated significant improvements in facial and total body repigmentation compared to placebo, meeting their co-primary endpoints. Based on these findings, Pfizer …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%This article analyzes Pfizer (PFE) and Eli Lilly (LLY) as contrasting investment opportunities within the pharmaceutical sector. Pfizer is presented as a value and income play due to its low valuation and high dividend yield, despite challenges like declining COVID-19 product sales and patent …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. European Commission grants marketing authorization for Pfizer and BioNTech's XFG-adapted COVID-19 vaccine for the 2026-2027 season in the EU. Approval covers use in …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%The European Commission has granted marketing authorization for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine, targeting the XFG variant, for individuals aged 6 months and older. This approval follows the EMA's recommendation to update vaccines to better protect against the XFG variant of the JN.1 …
Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy profile Shipping …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%The European Commission has granted marketing authorization for Pfizer and BioNTech's 2026-2027 monovalent XFG-adapted COVID-19 vaccine for individuals aged 6 months and older. This authorization, valid across 30 European countries, follows recommendations to target the XFG variant and is supported by data showing strong …
Pfizer PFE is set to report its second-quarter 2026 earnings on Aug. 4, before market open. The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $14.45 billion and 68 cents per share, respectively. Estimates for Pfizer's 2026 earnings …
Sharemaestro market context Price above Trend Line 52 weeks +22.2% · Next-week setup positive 56.8%Pfizer's PREVNAR 20™, a 20-valent pneumococcal conjugate vaccine, has been chosen for Québec's publicly funded pediatric immunization program, making it the second Canadian province to adopt it. This initiative aims to provide broader serotype coverage against severe pneumococcal disease in infants and children. Healthcare …
Pfizer Inc. had approximately 75,157 employees worldwide as of March 2026, marking an 8.3% decline from 2023. Despite the overall headcount reduction, Pfizer is actively hiring, with 2,887 active job postings in 2026, a 49.7% increase from the previous year. The company's workforce is …
Search by ticker symbol or company name and select a result to open its chart.